STO · ISOFOL.ST
Isofol Medical AB (publ)
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
Loading market information…
STO · IRLAB-A.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IRLAB Therapeutics AB (publ)’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IRLAB Therapeutics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 9.03M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
SEK 2.09+SEK 0.04 (+1.95%)
Initiator Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 42.74% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 0.24+SEK 0.01 (+2.13%)
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
